| Literature DB >> 29509698 |
Nasser K Awad1,2,3, Haitao Niu4, Usman Ali5,6, Yosry S Morsi7, Tong Lin8.
Abstract
Small-diameter blood vessels (SDBVs) are still a challenging task to prepare due to the occurrence of thrombosis formation, intimal hyperplasia, and aneurysmal dilation. Electrospinning technique, as a promising tissue engineering approach, can fabricate polymer fibrous scaffolds that satisfy requirements on the construction of extracellular matrix (ECM) of native blood vessel and promote the adhesion, proliferation, and growth of cells. In this review, we summarize the polymers that are deployed for the fabrication of SDBVs and classify them into three categories, synthetic polymers, natural polymers, and hybrid polymers. Furthermore, the biomechanical properties and the biological activities of the electrospun SBVs including anti-thrombogenic ability and cell response are discussed. Polymer blends seem to be a strategic way to fabricate SDBVs because it combines both suitable biomechanical properties coming from synthetic polymers and favorable sites to cell attachment coming from natural polymers.Entities:
Keywords: SDBVs; anti-thrombogenic agents; electrospinning; fibrous scaffold; thrombosis
Year: 2018 PMID: 29509698 PMCID: PMC5872197 DOI: 10.3390/membranes8010015
Source DB: PubMed Journal: Membranes (Basel) ISSN: 2077-0375
Figure 1Schematic illustration of blood vessel structure (reprinted from Ref. [16]).
Mechanical properties of natural blood vessels.
| Types | Elastic Modulus | Ultimate Stress | Strain at Failure | Burst Strength | Ref. |
|---|---|---|---|---|---|
| Saphenous vein (Circ.) | 43 | 3 | 11 | NA | [ |
| Saphenous vein (Long.) | 130 | 13 | 17 | NA | [ |
| Saphenous vein (Circ.) | 4.2 | 1.8 | 242 | 1680–3900 | [ |
| Saphenous vein (Long.) | 23.7 | 6.3 | 83 | NA | [ |
| Saphenous vein (Circ.) | 2.25 | 4 | 180 | 1250 | [ |
| Left internal mammary artery (Circ.) | 8 | 4.1 | 134 | 2000 | [ |
| Left internal mammary artery (Long.) | 16.8 | 4.3 | 59 | NA | [ |
| Femoral artery (Circ.) | 9–12 | 1–2 | 63–76 | NA | [ |
Circ.: circumferential; Long.: longitudinal; NA: not available.
Figure 2Electrospinning setups: (a) grounded flat collector is used to collect fibers; (b) tubular rotating mandrel is used to collect fibers to shape blood vessels.
Figure 3SEM photographs of (a) synthetic poly(ε-caprolactone) (PCL)/Poly(l-lactic acid) (PLA) blood vessel of 6 mm diameter, (b) the randomly oriented PCL fiber inner layer, (c) the aligned PLA fiber outer layer (reprinted from Ref. [34]).
Figure 4SEM image of polyurethane fibrous scaffold consists of micro-patterned internal layer and electrospun microfiber external layer; the ridge width, channel width and channel depth were 3.6 ± 0.2, 3.9 ± 0.1 and 0.9 ± 0.03 µm, respectively (reprinted from Ref. [40]).
Figure 5Tubular blood vessels fabricated by melt electrospinning: (a,b) polypropylene (Moplen 462R PP); (c,d) polylactide (PLA 4060D) (reprinted from Ref. [42]).
Figure 6SEM images of in vitro degradation of P (LLACL) fibrous scaffold in PBS at 37 °C after (a) 0 time, (b) 3 months (reprinted from Ref. [51]).
Small diameter blood vessels prepared and their mechanical properties.
| Polymers | Solvents | Operating Conditions | Mechanical Properties | Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Polymer Concentration | Voltage | Air Gap | Flow Rate | Spinning Time (min) | Mandrel Rotation Speed | Young’s Modulus | Maximum Stress (MPa) | Maximum Strain (%) | Burst Strength | |||
| PCL-PLA | CHCl3 | 12.5 | 13 | 20 | 0.6 | 180 | 3600 | 30.9 ± 6.6 | 4.3 ± 0.2 | 47.0 ± 6.3 | [ | |
| CHCl3/DMF | 14 | 13 | 20 | 1.5 | 180 | 10800 | 10.7 ± 0.3 | 1.2 ± 0.1 | 260 | |||
| PCL | CHCl3/EtOH | 15 | 20 | 12 | 6 | 4.8 | 600 | [ | ||||
| PCL | CHCl3/EtOH | 5–15 | 15–25 | 12–24 | 4500 | 2–7.4 | 200–1200 | [ | ||||
| TIPS-PEUU | HFIP | 8 | 10 | 1 | 250 | 1.4 ± 0.4 | 8.3 ± 1.7 | [ | ||||
| PCL | CHCl3/EtOH | 15 | 20 | 12 | 6 | 4.1 ± 0.5 | 1092 ± 28 | 3280 ± 280 | [ | |||
| PLCL | HFP | 9 | 15 | 1 | 500 | 1.2 ± 0.3 | 3.23 ± 0.57 | 270 | 933 ± 22 | [ | ||
| PCL | CHCl/MeOH | 5 | 18 | 2 | 17.44 ± 0.91 | 13.35 ± 1.47 | 168.4 ± 8.76 | [ | ||||
| 5 | 11 | 8 | 21.00 ± 1.39 | 8.72 ± 0.84 | 639.2 ± 24.15 | |||||||
| Silk | 10–11 | 0.9 | 3000 | 2.45 ± 0.47 | 2.42 ± 0.48 | 811 | [ | |||||
| Gelatine | TFE | 10 | 30 | 1.5 | 50 | 2 | 33.8 | 2.9 | 11.7 | [ | ||
| (rTE) | HFP | 15 | 18.5 | 12.5 | 2 | 4400 | 0.91 ± 0.16 | 0.36 ± 0.05 | 485 ± 25 | [ | ||
| PDO-elastin (50:50) | HFP | 100 g/mL and 200 mg/mL | 22 | 12 | 4 and 8 | 500 | 9.64 ± 0.66 | 3.25 ± 0.24 | 64.93 ± 3.97 | [ | ||
| Collagen-elastin-PLGA | HFP | −20 | 22 | 10 | 3 | 500 | 0.85 | 0.37 | [ | |||
| PLLACL coated with collagen | DCM/DMF | 0 | 10 | 1 | 5 | 150 | 16.6 ± 4.4 | 3.9 ± 0.3 | 292 ± 87 | [ | ||
| PEUU-PMBU | HFP | 15 | 10 | 15 | 1 | 5 | 250 | 3 ± 1 | 342 ± 43 | [ | ||
| PLA-Silk Fibroin-Gelatin | formic solution | 13 | 30 | 13 | 0.2 | 1000 | 2.21 ± 0.18 | 60.58 ± 1.23 | 1596 ± 20 | [ | ||
| CHCl3/EtOH | 5 | 25 | 15 | 0.1 | 2000 | |||||||
| PCL-collagen | HFP | 1 | 20 | 10 | 3 | 1000 | 2.7 ± 1.2 | 4.0 ± 0.4 | 140 ± 13 | 4915 ± 155 | [ | |
| PHBV-PCL | CHCl3 | 1 | 20 | 15 | 0.5 | 3000 | 22 ± 7 | 1.4 ± 0.3 | 30 ± 20 | [ | ||
| Collagen-hitosan-P(LLA-CL) | HFP/TFA | 14 | 12–15 | 1 | 10.3 ± 1.1 | 16.9 ± 2.9 | 112 ± 11 | >3365 ± 6 | [ | |||
| Lecithin-cholesterol-(Chol-PCL) | CHCl3/DMF | 18 | 15 | 3 | 35.92 ± 4.75 | 5.22 ± 0.50 | 107.15 ± 10.78 | [ | ||||
HFP: 1,1,1,3,3,3-hexafluro-2-propanol; TFE: 2,2,2-trifluoroethanol; DCM: dichloromethane; DMF: N,N-dimethylformamide; TFA: 2,2,2-trifluoroacetic acid.
Figure 7Endothelial cells cultured inside the micro-patterned polyurethane-based synthetic blood vessel after three days (reprinted from Ref. [40]).
Figure 8PCL/PLA nanofibrous scaffold cultured in 3T3 mouse fibroblasts cells for 4 weeks (reprinted from Ref. [34]).
Figure 9Expression of transgene eNOS protein in both MSCs seeded blood vessel (a,b) and eNOS-MSCs seeded blood vessel (c,d) (reprinted from Ref. [84]).
Figure 10Histological analysis for PCL electrospun blood vessel implanted in an abdominal aortic rat for 12 weeks (a) 20 time, (b) 100 time, (c), and (d) 200 time magnification (reprinted from Ref. [31]).
Figure 11Investigation of explanted (a) PCL graft and (b) PCL-arginine-glycine-aspartic acid (RGD) graft by stereomicroscope and (c,d) cross-section staining after four weeks of implantation. Acute thrombosis was observed in the lumen of PCL (reprinted from Ref. [89]).
Polymers used for the fabrication of small diameter blood vessels and their biostudies.
| Polymers | Cell Response | Ref. | |
|---|---|---|---|
| In Vitro Study | In Vivo Study | ||
| PCL-PLA | 3T3 mouse fibroblasts cells covered the surface of PCL/PAL fibrous scaffold after 4 weeks. Human venous myofibroblasts (HVS) cells were concentrated in the outer layer of PCL-PLA scaffold. | [ | |
| PCL | Implanted in a rat revealing that endothelilization and extra cellular matrix (ECM) formation of PCL was faster than PTFE commercial grafts. | [ | |
| PCL | In vivo implantation in rat for 12 weeks showed that the blood vessels were completely endothelilized with thrombosis formation. | [ | |
| TIPS-PEUU | Cell culture resulted in density up to 92 ± 1% using Adult stem cells. | [ | |
| PCL | Good patency rate, no thrombosis formation and rapid endothelilization up to 6 months of implantation in abdominal rat aorta. However, calcium deposition appeared after that at longer term of implantation. | [ | |
| PLCL | Smooth muscle cells (SMCs) were cultured for up to 7 weeks. The viability of cells increased by increasing cell culture time (11 × 105 cells after 7 weeks). | [ | |
| PCL | Thicker fiber diameter based PCL graft enhanced the formation of immunomodulatory and tissue remodeling (M2) phenotype when MSCs cells were cultured. | [ | |
| Silk | Human aortic endothelial cells and coronary artery smooth muscle cells experienced good proliferation. | [ | |
| (rTE) | Tropoelastin based blood vessel showed good endothelial cell response in terms of adhesion and proliferation. | [ | |
| PDO-Elastin (50:50) | Human dermal fibroblasts cells cultured on pure PDO and PDO-elastin blend for 7 days. Hybrid scaffold of PDO-elastin showed better cell response than pure PDO in terms of adhesion, proliferation and migration. | [ | |
| Collagen-elastin-PLGA | Ovine SMCs cultured on collagen/elastin/PLGA blend for 7 days demonstrating good cell viability (90%). | [ | |
| PLLACL coated with collagen | P LLA-CL-collagen vascular graft demonstrated good cell response when HCAECs are cultured. | P(LLA-CL)/collagen vascular graft demonstrated good patency without thrombosis formation when implanted in rabbit veins. | [ |
| PEUU-PMBU | Rat smooth muscle cells were cultured on PEUU/PMBU fibrous scaffold for 1 day resulting in diminishment of cell number (70–76%) compared to the control (TCPS) and pure PEUU. | Implanting the PEUU/ PMBU fibrous scaffold in rat abdominal aorta showed higher patency than PEUU. | [ |
| PLA-silk Fibroin-Gelatin | 3T3 mouse fibroblast cells cultured for 21 days on PLA/SF-gelatin showed good proliferation. | Subcutaneous implantation test in Sprague-dawley rat for 3 months resulted in biocompatibility of the graft. | [ |
| PCl-Collagen | Bovine endothelial cells (bECs) and smooth muscle cells (SMCs) were cultured on PCL-collagen fibrous scaffold demonstrating confluent layer of ECs on the lumen of the graft. | [ | |
| PHBV-PCL | RCEC cells experienced apoptosis on PHBV because of its stiffness. | [ | |
| Collagen-Chitosan-P(LLA-CL) | ECs cells demonstrated good adhesion and proliferation on collagen-chitosan-P(LLA-CL) compared to pure P(LLA-CL). | [ | |
| Lecithin-cholesterol-PCL | MSC cells were cultured for 7 days on both pure Chol-PCL and lecithin-Chol-PCL for 7 days. MSCs proliferated better on lecithin doped Chol-PCL. | [ | |